{"links":{"html":"https://www.erudio.com/reports/neonipiga-nct04006262","json":"https://www.erudio.com/reports/neonipiga-nct04006262.json","markdown":"https://www.erudio.com/reports/neonipiga-nct04006262.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"neonipiga-04006262"}},"request":"https://www.erudio.com/contact?report=neonipiga-04006262"},"offer":{"cited_commentary_sources":60,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a licence key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, to join with NPI-keyed systems such as a CRM. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":1950,"identity_verified_people":66,"optional":true,"price_per_verified_person_usd":15,"price_usd":990,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One licence key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"neonipiga-nct04006262"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the licence key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=neonipiga-04006262","people":"Tom and Audun, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/neonipiga-nct04006262","renewal":"Subscriptions are prepaid and do not renew automatically.","terms":"https://www.erudio.com/terms"},"size":"deep","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-08T16:02:35.345256Z","notify_subscribers":false,"status":"corrected","summary":"Duplicate cards for the same person were combined"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":11,"coverage":"discussed","id":"A1","source_count":8,"title":"Response-selected surgery avoidance"},{"claim_count":13,"coverage":"discussed","id":"A2","source_count":7,"title":"Chemotherapy omission versus chemoimmunotherapy"},{"claim_count":11,"coverage":"discussed","id":"A3","source_count":4,"title":"Dual versus single-agent immunotherapy and safety"},{"claim_count":11,"coverage":"discussed","id":"A4","source_count":7,"title":"pCR, survival and the threshold for practice change"},{"claim_count":13,"coverage":"discussed","id":"A5","source_count":5,"title":"Postoperative immunotherapy, chemotherapy or observation"},{"claim_count":17,"coverage":"discussed","id":"A6","source_count":10,"title":"Early MSI/MMR testing, confirmation and tumor heterogeneity"},{"claim_count":15,"coverage":"discussed","id":"A7","source_count":8,"title":"Surgery alone, downstaging needs and staging work-up"},{"claim_count":14,"coverage":"discussed","id":"A8","source_count":5,"title":"Guidelines, reimbursement and access-dependent treatment"},{"claim_count":17,"coverage":"discussed","id":"A9","source_count":11,"title":"Radiation and systemic-treatment alternatives"},{"claim_count":14,"coverage":"discussed","id":"A10","source_count":7,"title":"PD-L1 selection for perioperative chemotherapy-plus-immunotherapy"},{"claim_count":19,"coverage":"discussed","id":"A11","source_count":7,"title":"Duration, dose adaptation and postoperative treatment burden"},{"claim_count":26,"coverage":"discussed","id":"A12","source_count":10,"title":"Surveillance capacity, ctDNA, patient support and equitable implementation"}],"counts":{"cited_sources":61,"claims_by_expression_type":{"comparison":144,"experience":142,"interpretation":180,"opinion":225,"primary_context":9,"question":172,"restatement":197,"uncertainty":102,"unspecified":51},"claims_by_kind":{"attributed_opinion":45,"counterview":2,"interpretation":89,"limitation":37,"objective_result":1,"protocol_statement":1,"source_observation":1047},"evidence_units":662,"findings":12,"people_cited":72,"people_identity_verified":66,"people_total":91,"screened_sources":68,"verified_claims":1222},"depth":"rich","depth_rule":"thin if verified claims <30, findings <5, or cited sources <10; rich if verified claims >=100, findings >=8, and cited sources >=30; otherwise standard","findings_index":[{"id":"F1","title":"Organ preservation is compelling for selected responders, but clinical response does not settle the need for surgery"},{"id":"F2","title":"Immunotherapy incorporation attracts support; chemotherapy omission and the preferred combination remain contested"},{"id":"F3","publication_caveats":["Context for these views, not raised in the commentary cited above. The trial publication reports: Neoadjuvant therapy-related grade 3/4 adverse events occurred in six patients (19%). The rate of surgical morbidity (Clavien-Dindo classification) was 55% (one postoperative death occurred)."],"title":"Dual blockade's response appeal is limited by immune toxicity, while monotherapy remains a disputed alternative"},{"id":"F4","title":"High pCR is persuasive biological activity, not a demonstrated comparative survival advantage"},{"id":"F5","title":"After resection, clinicians separate perioperative immunotherapy from an unresolved adjuvant-only decision"},{"id":"F6","title":"Early tumor-specific testing and confirmation—not presumed MSI or a single positive biopsy—shape treatment choices"},{"id":"F7","title":"Surgery alone remains a conditional choice when downstaging is unnecessary or immediate local control matters"},{"id":"F8","title":"Funding and approval boundaries alter treatment delivered, even when clinicians favor immunotherapy"},{"id":"F9","title":"Radiation's role is disputed, with systemic-control arguments and selective exceptions kept distinct"},{"id":"F10","title":"For chemotherapy-plus-immunotherapy alternatives, PD-L1-negative disease prompts genuine disagreement about withholding treatment"},{"id":"F11","title":"Treatment duration and intensity are negotiated around response, postoperative recovery and tolerability"},{"id":"F12","title":"Organ preservation requires a surveillance-and-salvage system; ctDNA and patient support do not remove its limits"}],"medical_affairs_question":"What response definition, surveillance and salvage safeguards would address the concern about withholding a needed curative operation?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Organ preservation depends on proving response without sacrificing cure"},{"id":"section-2","level":2,"title":"Incorporating immunotherapy does not resolve chemotherapy omission"},{"id":"section-3","level":2,"title":"Response intensity, immune toxicity and the disputed monotherapy alternative"},{"id":"section-4","level":3,"title":"Curative-treatment risk remains setting-specific"},{"id":"section-5","level":3,"title":"The connected safety exchange explains holding and avoiding rechallenge"},{"id":"section-6","level":2,"title":"High pCR is persuasive biological activity, not a demonstrated comparative survival advantage"},{"id":"section-7","level":2,"title":"After resection, clinicians separate perioperative immunotherapy from an unresolved adjuvant-only decision"},{"id":"section-8","level":2,"title":"Early tumor-specific testing and confirmation—not presumed MSI or a single positive biopsy—shape treatment choices"},{"id":"section-9","level":2,"title":"Surgery alone: downstaging and prompt local control define the exception"},{"id":"section-10","level":2,"title":"Access: preferred immunotherapy is not always delivered"},{"id":"section-11","level":2,"title":"Radiation: systemic control, selective local treatment and nonsurgical uncertainty"},{"id":"section-12","level":2,"title":"PD-L1-negative disease: different thresholds for offering or withholding"},{"id":"section-13","level":2,"title":"Duration and intensity: tested schedules are not proven optima"},{"id":"section-14","level":3,"title":"Retaining treatment while adjusting its burden"},{"id":"section-15","level":3,"title":"Front-loading and postoperative continuation have different qualifications"},{"id":"section-16","level":2,"title":"Organ preservation depends on access to surveillance and salvage"},{"id":"section-17","level":3,"title":"Concrete surveillance practices, not interchangeable protocols"},{"id":"section-18","level":3,"title":"ctDNA may complement response assessment, not certify safe observation"},{"id":"section-19","level":3,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, na, single group, phase2"},"identity":{"accepted_at":"2026-10-08T16:02:35.345256Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-07T22:54:07Z","record_hash":"86fb3aee518bfef9aaa04db5f5ec1dd0039675d0cc855fcf8534bb3d91b69cd6","release_hash":"791593395914ae13f346c571216464187f6abd57d1363682872c5c3f69c36118","report_id":"erudio-nct04006262","run_id":"1ee72c28-8c72-4c3d-8fd9-a35551779163","schema_version":"5.0","slug":"neonipiga-04006262","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"NEONIPIGA prompts a practical question: can immunotherapy replace chemotherapy before surgery for resectable stomach or gastroesophageal-junction cancer with deficient mismatch repair or high microsatellite instability? Clinicians discuss response-selected surgery avoidance, dual versus single-agent immunotherapy, toxicity, response and survival endpoints, postoperative treatment, biomarker confirmation, staging, radiation alternatives and PD-L1 selection for chemotherapy-plus-immunotherapy regimens. Other topics include treatment duration, reimbursement, surveillance, circulating tumor DNA, patient support and access to follow-up.","meta_description":"68 HCP sources screened · 1222 verified claims from 61 sources · 12 findings. Updated 2026-10-08.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-a57eac7758096554b41a"],"id":"F1","paraphrase":"An X-thread author asked how to specify a complete clinical response and plan surveillance for a possible watch-and-wait pathway in dMMR gastric or gastroesophageal-junction cancer.","source_channel":"x_thread","source_date":"2022-08-17","title":"Organ preservation is compelling for selected responders, but clinical response does not settle the need for surgery"},{"cited_claim_ids":["claim-dcba8a8a43469c362e4f"],"id":"F12","paraphrase":"A guest in a YouTube discussion asked who is represented in the evidence and databases supporting circulating tumor DNA and RNA sequencing tests, and whether measurements are comparable across ancestry groups and disease types.","source_channel":"youtube","source_date":"2026-02-09","title":"Organ preservation requires a surveillance-and-salvage system; ctDNA and patient support do not remove its limits"}]},"publication":{"approved_at":"2026-10-07T22:54:07Z","approved_by":"Audun Utengen","corrections":[{"affected_ids":["F3"],"date":"2026-10-08T16:25:00Z","summary":"Publication caveats shown beside their findings"},{"affected_ids":[],"date":"2026-10-09T02:03:00Z","summary":"internal identifiers removed from public text"},{"affected_ids":["F3"],"date":"2026-10-09T02:03:00Z","summary":"Publication caveats shown beside their findings"},{"affected_ids":[],"date":"2026-10-08T20:30:00Z","summary":"Duplicate cards for the same person were combined"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"1.0","scope_and_limits":{"commentary_scope":{"basis":"Reviewed retained sources only; not all HCPs or all public discussion.","empty_source_ids":[],"has_known_gaps":true,"held_out_finds":16,"retrieval_gaps":["commentary:coverage_scope:keyword matches to trial identifier and registry aliases; single-letter acronym variants require planned context in the same indexed chunk; unnamed references or other transcription variants may be absent","commentary:source_unreadable:podcast:episode_id:31ffe7:SourceAcquisitionError:public speaker turns disagree with stored chunk text","commentary:indexed_source_unreadable:youtube:video_id:_dvmNgixvmM:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:indexed_source_unreadable:youtube:video_id:hsWDBCn2agg:SourceAcquisitionError:Erudio MCP fetch_source_transcript rejected the source request","commentary:scribe_unavailable:mcp:podcast:7fe157: diarized re-transcription failed; quotes use the discovery transcript.","commentary:scribe_unavailable:mcp:youtube:TEclVr0mDf4: diarized re-transcription failed; quotes use the discovery transcript.","commentary:scribe_unavailable:mcp:youtube:ZQZOwUU0oik: diarized re-transcription failed; quotes use the discovery transcript.","commentary:scribe_unavailable:mcp:youtube:_0Dwm-LhtUM: diarized re-transcription failed; quotes use the discovery transcript.","commentary:held_out:mcp:podcast:260047@99828:102319,mcp:podcast:260047@97097:99826: a claim turns Wainberg's statement about nivolumab being standard “in these patients” into a broad early-stage gastric/esophageal endorsement. mcp:podcast:260047@97097:99826 establishes the residual-pathology, post-chemoradiation/esophagectomy context; mcp:podcast:260047@99828:102319 separately leaves pCR management unresolved and says he did not then give checkpoint inhibitors in early-stage gastric cancer.","commentary:held_out:mcp:podcast:260047@19350:22395: a claim assigns the almost-80% major-pathological-response estimate specifically to Neo-Nepiga, although the speaker says these data were partly from Memorial in esophageal disease. Its qualifier acknowledges that separate provenance but does not correct the statement's trial-specific assignment.","commentary:held_out:mcp:podcast:70c027@19438:19540,mcp:podcast:70c027@18934:19362: a claim says the referent of “those” is not made more specific. The adjacent mcp:podcast:70c027@18934:19362 identifies stage II/III rectal-cancer access difficulties, and mcp:podcast:70c027@19438:19540 continues that speaker's account by saying those cases could be appealed.","commentary:held_out:mcp:podcast:70c027@20700:20914,mcp:podcast:70c027@20988:21823: a claim says the endometrial comparison is not completed, and a claim calls the compared response setting unspecified. After an interruption, mcp:podcast:70c027@20988:21823 completes the same speaker's endometrial-versus-rectal comparison before asking about GE-junction tumors.","commentary:held_out:mcp:podcast:0e9fbf@51167:53530: The connected perioperative discussion includes an unidentified speaker's view that CPS counting and TAP assessment are more similar than different, despite differing diagnostic partners. That assay-comparison view is absent from the supplied inventory and bound quotations.","commentary:held_out:mcp:podcast:e82719@7750:10390: Klempner's connected perioperative commentary explains why MATTERHORN changed his practice for operable patients: reported EFS and now OS improvements, while longer follow-up was still needed to define a five-year cure rate. This treatment preference and its maturity qualification are absent from the supplied inventory and bound quotations.","commentary:held_out:mcp:podcast:e82719@10392:11735: Klempner argues that FLOT is deployable using reported delivery in the large global trial: more than 90% received the neoadjuvant component, whereas about three quarters could start adjuvant FLOT. This distinct feasibility interpretation is absent; starting postoperative treatment must not become completing it.","commentary:held_out:mcp:youtube:tvSEpU9QM_Q@12292:12920: Kim explicitly describes a practice change after KEYNOTE-585: she was not adding a PD-1 inhibitor for residual disease after neoadjuvant FLOT, although she had previously added one when surgery showed no clear pathological response. a claim retains her general concern but not this treatment-history-specific withholding decision.","commentary:held_out:mcp:youtube:tvSEpU9QM_Q@13391:14666: Kim explains why poor postoperative pathology does not automatically make her change or withhold adjuvant treatment: she continues the same regimen and weighs improved scans and symptoms, while questioning whether pathology fully captures prior treatment effect. This consequential continuation rationale is absent.","commentary:held_out:mcp:youtube:tvSEpU9QM_Q@14810:15447: Kim reports a selective exception to the report's otherwise cautious ctDNA account: after difficult neoadjuvant treatment and a strong surgical response, serial negative ctDNA may lead her to avoid adjuvant treatment when safety or patient willingness is concerning. This actual conditional de-escalation practice is absent.","commentary:held_out:mcp:youtube:tvSEpU9QM_Q@15852:16580: Kim's answer gives a specific reason ctDNA alone is insufficient: sensitivity below her comfort level and poor shedding in brain, lung and peritoneal sites. She proposes pairing it with other technologies, such as methylation assays. The inventory retains later negative-test failures but not this assay limitation or proposed complement.","commentary:held_out:mcp:youtube:tvSEpU9QM_Q@71990:72208,mcp:youtube:tvSEpU9QM_Q@72277:72468,mcp:youtube:tvSEpU9QM_Q@72533:72817,mcp:youtube:tvSEpU9QM_Q@72881:73144: The unidentified questioner's later reply goes beyond the earlier timing question in a claim: for high-marker gastric adenocarcinoma with poor FLOT response, the speaker would rather try immunotherapy before metastatic disease because potentially responsive patients may be hidden in that group. The speaker acknowledges uncertainty and frames this as personal or patient-dependent logic.","commentary:held_out:mcp:youtube:tvSEpU9QM_Q@73146:73299: Kim responds to that postoperative discussion by characterizing a patient with pathological T4N3 disease as “metastatic at that point.” This consequential, potentially mistaken clinical characterization is absent and must be retained as her statement, not converted into a verified M1 status.","commentary:held_out:mcp:podcast:2cd537@22131:25062: a claim juxtaposes Matterhorn with a pCR increase using either FLOT or 5-FU-based chemotherapy without preserving the unresolved study referent. mcp:podcast:2cd537@22131:25062 discusses KEYNOTE-585 and Matterhorn together; it does not clearly assign that two-backbone response observation to Matterhorn. a claim preserves this uncertainty in the parallel account.","commentary:held_out:mcp:youtube:ZQZOwUU0oik@17480:18877,mcp:youtube:ZQZOwUU0oik@18879:20652: a claim qualifies the protocol's study as unidentified. The immediately preceding mcp:youtube:ZQZOwUU0oik@17480:18877 explicitly discusses patients enrolled on Matterhorn receiving dose modifications, and mcp:youtube:ZQZOwUU0oik@18879:20652 answers that discussion by explaining investigator flexibility and the protocol's intended discretion. The surrounding supplied exchange resolves the study context."],"source_count":68,"unreadable_unit_ids":[]},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Sources were found by searching for the trial's name, registry number and known aliases. Discussion that refers to the trial without naming it may be missing.","1 matching source (1 podcast) could not be read and is not included.","For 4 recordings, a transcript separated by speaker was not available, so quotes come from the original automatic transcript and may lack speaker labels.","16 points raised by the independent review are not yet resolved in this edition, such as a clinician view not yet captured as evidence or a qualifier to restore. The next refresh takes them up.","2 further source limits are recorded in the machine-readable scope of this record.","The reviewed commentary comes from 68 retained sources, not 68 independent clinicians. Some recordings appear in more than one publication format, and several posts repeat the same study summary; repetition should not be interpreted as independent agreement.","Some public discussions could not be reviewed, and searches focused on the trial identifier and indexed trial names. Unnamed references and unusual transcriptions may therefore be absent, limiting claims about the breadth of the conversation.","Several recordings rely on the available written transcript rather than a separately checked recording. Some passages establish no speaker name, or only a first name; adjacent named comments do not establish who voiced those passages.","Study names, regimens and numerical descriptions sometimes differ between accounts or remain unclear. They are retained as what the speaker reported, not reconciled into corrected clinical facts. Thomas Samaille's reported pCR figure, for example, differs from the verified publication result.","Guideline, approval and reimbursement statements describe the speaker's setting and the evidence available during that discussion. They do not establish current global availability, and publication dates are not automatically session or readout dates.","NEONIPIGA's single-arm phase II context and the surgical pCR denominator limit comparative conclusions. Other-study comparisons and individual experiences do not establish superiority, equivalent efficacy or a survival benefit from omitting chemotherapy or surgery.","Allan Pereira's posts are attributable to the named author, but his clinical role is explicitly unresolved in the supplied professional context. His interpretations are retained as attributed commentary, not additional verification of clinical practice.","The report preserves views from different timepoints and clinical settings. Apparent differences between a clinician's comments do not, by themselves, establish a change of mind."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":21,"publication":1,"registry":0,"regulatory":0,"x_thread":25,"x_video":0,"youtube":14},"by_evidence_role":{"commentary":60,"results":1},"count":61,"evidence_window":{"end":"2026-09-28","start":"2022-01-20"},"retrieval_snapshot":"2026-10-08T09:36:14.313912Z","timeline":[{"count":2,"week":"2022-W03"},{"count":1,"week":"2022-W28"},{"count":1,"week":"2022-W29"},{"count":1,"week":"2022-W32"},{"count":2,"week":"2022-W33"},{"count":1,"week":"2023-W02"},{"count":1,"week":"2023-W03"},{"count":1,"week":"2023-W04"},{"count":1,"week":"2023-W10"},{"count":1,"week":"2023-W28"},{"count":1,"week":"2023-W42"},{"count":2,"week":"2023-W43"},{"count":1,"week":"2023-W49"},{"count":2,"week":"2024-W06"},{"count":1,"week":"2024-W16"},{"count":1,"week":"2024-W17"},{"count":1,"week":"2024-W18"},{"count":1,"week":"2024-W23"},{"count":1,"week":"2024-W29"},{"count":1,"week":"2024-W30"},{"count":1,"week":"2024-W31"},{"count":1,"week":"2024-W44"},{"count":4,"week":"2024-W51"},{"count":1,"week":"2025-W06"},{"count":1,"week":"2025-W07"},{"count":1,"week":"2025-W08"},{"count":1,"week":"2025-W10"},{"count":2,"week":"2025-W13"},{"count":1,"week":"2025-W25"},{"count":2,"week":"2025-W27"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2025-W32"},{"count":5,"week":"2025-W33"},{"count":2,"week":"2025-W39"},{"count":2,"week":"2025-W47"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W03"},{"count":1,"week":"2026-W07"},{"count":1,"week":"2026-W20"},{"count":1,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":2,"week":"2026-W25"},{"count":2,"week":"2026-W37"},{"count":1,"week":"2026-W40"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT04006262:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04006262:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:32057467","quote_policy":"short_quote_link_out"},{"id":"pubmed:35969830","quote_policy":"no_derivatives"},{"id":"mcp:podcast:0e9fbf","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:174ad1","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:229f29","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:260047","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:2cd537","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:3cb661","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:55ddd4","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:56bc7a","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:70c027","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7a4b8c","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:7fe157","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a7e2fd","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:a8c007","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:b9680b","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:bfe626","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:c13bd6","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:d30683","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:d4900e","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:d9ddee","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:e82719","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:f7debc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1484249678883409922:353b01e5-1557-43df-a27f-962455d4eb0a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1484254559375527936:ba78c2f1-cd5e-4788-beb1-1588fe9f0a95","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1548250525644124160:650cc510-1ca3-455c-bf74-dc48fcabfdf7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1557836071458803714:0b0feaee-add6-4bb4-8c82-840b419e9ac4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1559966244299689985:ab800c10-ed60-4993-9ddb-0203f7c21b1b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1560958074617217025:31970bb2-c17c-48b6-a0c2-5e14f7c0a08c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1563133689227517952:2704c5cb-c403-447d-919e-04719fa3d352","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1568004520285974529:55b67b8a-b5f4-42b7-afb7-66cfbe2ab9be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1614557314962567169:ea787296-5fb8-4d8a-a69f-89010861752f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1616158686899994649:c07af493-87e8-474b-b037-b5d73d9f174b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1618057668857565184:67bd1fdb-ea4f-4de3-b290-de8c40c03cf4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1754889072340803888:39c3b8ed-69df-4441-82ed-10b495101084","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1798814878133809309:34a8048a-c7dd-45ad-a292-63198180c07f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1806608198691963197:2f25afc0-b93b-4131-a3b2-6a933281ccc4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1897621127390015924:b8dd8fe2-bf05-4070-ad50-10730853580d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1904922619117191470:3f08b278-e4dd-4065-9e25-183be6070ce7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1915048975670939800:fb7b62b2-9a13-4b6b-8632-01d5137e8633","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1942349615334113627:2e373ff0-5b65-49a4-8f35-313695dcd144","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1955926199634362609:84945047-3689-434b-8d4a-90eaf7d24f31","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1955926431172550692:0654b1d0-17c1-4807-b181-2420f0b44375","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1955926587007791255:c2ca5b45-f2f4-47b1-be75-0a0a2f575071","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1955926858341511616:b9432723-df1b-4f67-82b7-52d5185856d8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1965976543403897124:a7daffb4-3765-4438-9f63-6dd843eb2edb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1991818993460539851:a69c3289-a6c4-43dd-b037-1a41c6386a48","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1992071365009224170:8756a01d-0709-421c-a743-bcdb7b8e3547","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1992491973920555189:3dc76f17-d196-407d-b102-d1a288a8d5fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2009191302584570315:c3ba53c4-5549-44b7-a66c-e904bd015172","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2053811554483679250:07664387-b164-4740-ba4b-3f49c0bb68e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2059571550303494422:49177a40-73ef-4130-b5be-a69b4d1ab92a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060332937661354019:d6dd0a74-4694-4b25-90af-775fa7767884","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2080758404746760323:c9403d13-719a-4452-bc03-17d88c3ec4f3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098043181950541831:78f0b873-b9a3-44e0-8ca6-e0f8d2a14452","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2098167009909649615:c5bdcdab-f82b-4df3-a256-9a7699309a82","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:GhgQ5OIbIkM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:GkNF-9uC90o","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:IFwQSHG9vX4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:PFH5Z4AA90Q","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:TEclVr0mDf4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:WlOheLEUQ3k","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ZQZOwUU0oik","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:ZnOpPCU6VMw","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:_0Dwm-LhtUM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:_AwvPRb3n18","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:fNaHKBXBBOE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:smwtLyzDbGU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:tvSEpU9QM_Q","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:uoKN6cdwR_s","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":21,"publication":0,"registry":0,"regulatory":0,"x_thread":33,"x_video":0,"youtube":14},"by_evidence_role":{"commentary":68},"count":68,"evidence_window":{"end":"2026-09-28","start":"2022-01-20"},"retrieval_snapshot":"2026-10-08T09:36:14.313912Z","timeline":[{"count":2,"week":"2022-W03"},{"count":1,"week":"2022-W28"},{"count":1,"week":"2022-W29"},{"count":1,"week":"2022-W32"},{"count":2,"week":"2022-W33"},{"count":1,"week":"2022-W34"},{"count":1,"week":"2022-W36"},{"count":1,"week":"2023-W02"},{"count":1,"week":"2023-W03"},{"count":1,"week":"2023-W04"},{"count":1,"week":"2023-W10"},{"count":1,"week":"2023-W28"},{"count":1,"week":"2023-W42"},{"count":2,"week":"2023-W43"},{"count":1,"week":"2023-W49"},{"count":2,"week":"2024-W06"},{"count":1,"week":"2024-W16"},{"count":1,"week":"2024-W17"},{"count":1,"week":"2024-W18"},{"count":1,"week":"2024-W23"},{"count":1,"week":"2024-W26"},{"count":1,"week":"2024-W29"},{"count":1,"week":"2024-W30"},{"count":1,"week":"2024-W31"},{"count":1,"week":"2024-W44"},{"count":4,"week":"2024-W51"},{"count":1,"week":"2025-W06"},{"count":1,"week":"2025-W07"},{"count":1,"week":"2025-W08"},{"count":1,"week":"2025-W10"},{"count":2,"week":"2025-W13"},{"count":1,"week":"2025-W17"},{"count":1,"week":"2025-W25"},{"count":2,"week":"2025-W27"},{"count":1,"week":"2025-W28"},{"count":1,"week":"2025-W32"},{"count":5,"week":"2025-W33"},{"count":1,"week":"2025-W37"},{"count":2,"week":"2025-W39"},{"count":3,"week":"2025-W47"},{"count":1,"week":"2025-W50"},{"count":1,"week":"2026-W02"},{"count":1,"week":"2026-W03"},{"count":1,"week":"2026-W07"},{"count":1,"week":"2026-W20"},{"count":2,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":2,"week":"2026-W25"},{"count":1,"week":"2026-W30"},{"count":2,"week":"2026-W37"},{"count":1,"week":"2026-W40"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Opdivo"],"label":"nivolumab","slug":"nivolumab"},{"brand_names":["Yervoy"],"label":"ipilimumab","slug":"ipilimumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Gastroesophageal adenocarcinoma","slug":"gastroesophageal-adenocarcinoma"},{"reason":"Unmapped registry condition: MSI and or dMMR","status":"unmapped"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"NEONIPIGA","aliases":["NEONIPIGA","Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.","Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma: An Open-label GERCOR Phase II Study"],"brief_title":"Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.","collaborators":["Bristol-Myers Squibb"],"conditions":["Localized Oesogastric Adenocarcimona","MSI and or dMMR"],"enrollment":{"count":32,"type":"ESTIMATED"},"excluded_lookalike_trials":{"reason":"No owner-reviewed lookalike exclusion list.","status":"not_set"},"interventions":[{"name":"Nivolumab 10 MG/ML","synonyms":["Opdivo"],"type":"DRUG"},{"name":"Ipilimumab 200 MG in 40 ML Injection","synonyms":["Yervoy"],"type":"DRUG"}],"nct_id":"NCT04006262","official_title":"Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma: An Open-label GERCOR Phase II Study","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2025-10","type":"ESTIMATED"},"primary_endpoints":[{"description":"Each center will assess the pathologic response with a centralized center review in case of cPRR and the analysis will be in intention-to-treat (ITT). cPRR will be defined as complete tumor disappearance of tumor in the low esophagus or the stomach (from 1/3 inferior of the esophagus to pylorus) after surgery anatomopathologic examination according to mandard scale. Surgery will be performed within 5 weeks +\\\\- 1 week after the last cycle (cycle 6) of neoadjuvant therapy","measure":"Complete pathological response (cPRR) rate","timeFrame":"time point when the tumor is examined after the surgery (up to 30 months)"}],"registry_last_updated":"2025-06-15","registry_url":"https://clinicaltrials.gov/study/NCT04006262","short_name":"NEONIPIGA","short_name_basis":"registry_acronym","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","start_date":{"date":"2019-10-23","type":"ACTUAL"},"study_design":"interventional, na, single group, phase2","study_ids":[{"id":"NEONIPIGA - D18-02","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}